

VISMODEGIB (Erivedge)

INDICATION (ICD10) C44

Check the most recent Blueteq eligibility criteria before prescribing. Blueteq registration required. (www.england.nhs.uk/publication/national-cancer-drugs-fund-list/) (VIS2)

1. For patients with multiple basal cell carcinomas (BCC) in adults, either- Gorlin syndrome with non-locally advanced, non-metastatic multiple basal cell carcinomas (BCC) (≥ 6) clinically evident at the point of decision to treat BCCs of which 3 are at least 5mm OR non-locally advanced, non-metastatic multiple BCC (≥ 6) clinically evident at the point of decision to treat BCCs of which 3 are at least 5mm AND are appropriate for surgery i.e. surgically eligible tumours. At least 6 operable clinically evident non-locally advanced, non-metastatic BCC with surgically eligible tumours of 3 lesions of at least 5mm diameter, of which at least 1 is histopathologically confirmed and is suitable for surgical intervention, but surgical intervention alone has the potential for substantial disfigurement. PS 0, 1 or 2.

REGIMEN

Day 1 VISMODEBIB 150mg orally once daily continuously

CYCLE FREQUENCY AND NUMBER OF CYCLES

Continuous every 28 days until disease progression.

Or on an intermittent schedule but Trust policy regarding the use of unlicensed treatments has to be followed as vismodegib and the recommended intermittent schedules are not licensed in this indication:

A 72 week period of: vismodegib 12 weeks; off treatment 8 weeks; vismodegib 12 weeks; off treatment 8 weeks; vismodegib 12 weeks; off treatment 8 weeks; vismodegib 12 weeks

A 72 week period of: vismodegib 24 weeks; off treatment 8 weeks; vismodegib 8 weeks; off treatment 8 weeks; vismodegib 8 weeks; off treatment 8 weeks; vismodegib 8 weeks

ADMINISTRATION

Available as 150mg capsules

Swallow whole with water, with or without food.

ANTI-EMETICS

Minimal emetic risk

CONCURRENT MEDICATION REQUIRED

Vismodegib	None required
------------	---------------

INVESTIGATIONS

Blood results required before SACT administration

FBC, U&E and LFTs every cycle

Neutrophils x $10^9/L$ ≥ 1.5

Platelets x $10^9/L$ ≥ 100

Serum creatinine every cycle

MAIN TOXICITIES AND ADVERSE REACTIONS

Vismodegib	Arthralgia and musculoskeletal pain. Diarrhoea and vomiting Hair loss Hepatotoxicity Hyponatraemia Muscle spasms Skin rash Taste disturbances
------------	--

INTERACTIONS WHICH MAY REQUIRE DOSE MODIFICATIONS

(not exhaustive list check SPC/BNF/Stockleys)

Vismodegib	
------------	--

REFERENCES

1. SPC
2. Dreno, B., Kunstfeld, R., Hauschild, A., Fosko, S., Zloty, D., Labeille, B., Grob, J-J. et al. (2017) Two intermittent vismodegib dosing regimens in patients with multiple basal-cell carcinomas (MIKIE): a randomised regimen-controlled, double-blind, phase 2 trial. *The Lancet Oncology* 18:404-12.